Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 58

Results For "safety"

1080 News Found

Dozee and Midmark to launch India’s first intelligent connected bed with Remote Patient Monitoring and EWS
Digitisation | August 24, 2022

Dozee and Midmark to launch India’s first intelligent connected bed with Remote Patient Monitoring and EWS

The intelligent connected bed is one of the most significant breakthroughs in India’s journey to create a world-class connected healthcare system to deliver quality healthcare to a billion Indians.


USFDA grants emergency use authorization for Novavax COVID-19 vaccine
Drug Approval | August 22, 2022

USFDA grants emergency use authorization for Novavax COVID-19 vaccine

Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.


CureVac, GSK start Phase 1 clinical study of omicron-targeting COVID-19 vaccine candidate
Diagnostic Center | August 19, 2022

CureVac, GSK start Phase 1 clinical study of omicron-targeting COVID-19 vaccine candidate

Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines


Sanofi updates on amcenestrant clinical development program
Diagnostic Center | August 18, 2022

Sanofi updates on amcenestrant clinical development program

The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial


Philips CEO Frans van Houten to step down; Roy Jakobs named successor
People | August 18, 2022

Philips CEO Frans van Houten to step down; Roy Jakobs named successor

The Supervisory Board has unanimously decided to propose Roy Jakobs as the next President and CEO of Royal Philips to its General Meeting of Shareholders.


Short Wave Pharma signs clinical trial agreement with the Sheeba Research Fund
Diagnostic Center | August 16, 2022

Short Wave Pharma signs clinical trial agreement with the Sheeba Research Fund

The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.


Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222
Diagnostic Center | August 16, 2022

Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222

WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".


ENHERTU delays disease progression in DESTINYBreast02 Phase 3 Trial
Diagnostic Center | August 15, 2022

ENHERTU delays disease progression in DESTINYBreast02 Phase 3 Trial

Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients


Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
News | August 13, 2022

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease


Pfizer announces positive results from Phase 3 study of 20-valent pneumococcal conjugate vaccine
Diagnostic Center | August 13, 2022

Pfizer announces positive results from Phase 3 study of 20-valent pneumococcal conjugate vaccine

Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA